secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001549595-24-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics outlines 2024 priorities: BTK degrader NX-5948 acceleration, partial hold on NX-2127
--------------------------------------------------------------------------------

- Positive Phase 1 data for NX-5948 (BTK degrader) in CLL/NHL; plans to accelerate enrollment toward pivotal trials.
- NX-2127 Phase 1 partial clinical hold; Nurix expects to resolve with new drug product in ongoing trial.
- Gilead licensed oral IRAK4 degrader NX-0479 for $20M fee; up to $425M milestones plus tiered royalties.
- Pfizer (Seagen) collaboration for Degrader-Antibody Conjugates; $60M upfront, up to $3.4B milestones.
- Cash of $329M (Aug 2023) plus $60M from Pfizer; runway into H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000003/0001549595-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000003/nrix-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer